RBC
GALT icon

Ronald Blue & Co’s Galectin Therapeutics GALT Stock Holding History

Ronald Blue & Co’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16,000
Closed -$24K – 229
2016
Q2 		$24K Hold
16,000
– – ﹤0.01% 228
2016
Q1 		$23K Hold
16,000
– – ﹤0.01% 201
2015
Q4 		$26K Hold
16,000
– – ﹤0.01% 184
2015
Q3 		$37K Hold
16,000
– – ﹤0.01% 298
2015
Q2 		$44K Buy
+16,000
New +$48.2K ﹤0.01% 354

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Ronald Blue & Co's GALT Position: Q3 2016 in Review

Ronald Blue & Co sold out of Galectin Therapeutics (GALT) in Q3 2016, closing a stake of 16,000 shares — an estimated $24K sold.

Ronald Blue & Co first reported a position in GALT in Q2 2015 and held it in 5 quarters. The position peaked at $44K in Q2 2015. 46 funds tracked by Wall St. Rank hold GALT as of Q3 2016.

  • Ronald Blue & Co reported no remaining Galectin Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Ronald Blue & Co sold 16,000 Galectin Therapeutics shares in Q3 2016, an estimated $24K.
  • Ronald Blue & Co first reported a position in Galectin Therapeutics in Q2 2015 and held it in 5 quarters.
  • Ronald Blue & Co's Galectin Therapeutics position peaked at $44K in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2016.

Based on Ronald Blue & Co's 13F filing for Q3 2016, filed 17 Oct 2016.